Jed A. Latkin
2017
In 2017, Jed A. Latkin earned a total compensation of $814.4K as Chief Executive Officer, Chief Operating Officer and Chief Financial Officer at Navidea Biopharmaceuticals, a 150% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $366,653 |
|---|---|
| Option Awards | $125,833 |
| Salary | $316,458 |
| Other | $5,429 |
| Total | $814,373 |
Latkin received $366.7K in non-equity incentive plan, accounting for 45% of the total pay in 2017.
Latkin also received $125.8K in option awards, $316.5K in salary and $5.4K in other compensation.
Rankings
In 2017, Jed A. Latkin's compensation ranked 9,945th out of 14,666 executives tracked by ExecPay. In other words, Latkin earned more than 32.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,945 out of 14,666 | 32nd |
Division Manufacturing | 3,846 out of 5,770 | 33rd |
Major group Chemicals And Allied Products | 1,337 out of 2,074 | 36th |
Industry group Drugs | 1,083 out of 1,730 | 37th |
Industry In Vitro and In Vivo Diagnostic Substances | 41 out of 72 | 43rd |
Source: SEC filing on June 28, 2019.
Latkin's colleagues
We found two more compensation records of executives who worked with Jed A. Latkin at Navidea Biopharmaceuticals in 2017.
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019